Literature DB >> 18253153

Genetic modification of neural stem cells.

Rahul Jandial1, Ilyas Singec, Christopher P Ames, Evan Y Snyder.   

Abstract

Neural stem cells (NSCs) are the main vehicle for genetic and molecular therapies in the central nervous system (CNS). The sustainability of NSCs has been ensured through genetic manipulation both in vitro and in vivo. NSC lines have also been immortalized and controlled for cell growth in similar fashion. Their potential to differentiate and their genetic plasticity make them the modality of choice for cellular transplantation. After transplantation, NSCs also exhibit inherent long-distance migratory capabilities and a remarkable capacity to integrate into brain structures. This makes NSCs the ideal candidate for delivery and expression of therapeutic genes. Mouse models of CNS diseases have already demonstrated the efficacy of such NSC-mediated treatment, and further investigations are underway to bridge the gap into true clinical application. Finally, the imaging possibilities with NSC transplants are endless, and they will be a pivotal component to safe and effective human transplantation. This paper provides an overview on NSCs and the various methods in which they have been genetically manipulated for biological investigation.

Entities:  

Mesh:

Year:  2008        PMID: 18253153     DOI: 10.1038/sj.mt.6300402

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  15 in total

1.  Gene and stem cell therapy: alone or in combination?

Authors:  Mohammad A Rafi
Journal:  Bioimpacts       Date:  2011-12-09

2.  Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone.

Authors:  Ester J Kwon; Jurate Lasiene; Berit E Jacobson; In-Kyu Park; Philip J Horner; Suzie H Pun
Journal:  Biomaterials       Date:  2009-12-09       Impact factor: 12.479

3.  In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas.

Authors:  Mahmud Uzzaman; Gordon Keller; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

Review 4.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Neural progenitor cells labeling with microbubble contrast agent for ultrasound imaging in vivo.

Authors:  Wenjin Cui; Sidhartha Tavri; Michael J Benchimol; Malak Itani; Emilia S Olson; Hong Zhang; Marika Decyk; Rosemarie G Ramirez; Christopher V Barback; Yuko Kono; Robert F Mattrey
Journal:  Biomaterials       Date:  2013-04-08       Impact factor: 12.479

6.  Nanoparticle-mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat brain.

Authors:  Xiaowei Li; Stephany Y Tzeng; Xiaoyan Liu; Markus Tammia; Yu-Hao Cheng; Andrew Rolfe; Dong Sun; Ning Zhang; Jordan J Green; Xuejun Wen; Hai-Quan Mao
Journal:  Biomaterials       Date:  2016-01-20       Impact factor: 12.479

Review 7.  Gene delivery strategies to promote spinal cord repair.

Authors:  Christopher M Walthers; Stephanie K Seidlits
Journal:  Biomark Insights       Date:  2015-04-09

8.  Differentiation of rhesus adipose stem cells into dopaminergic neurons.

Authors:  Yan Zhou; Maosheng Sun; Hongjun Li; Min Yan; Tianhong Xie
Journal:  Neural Regen Res       Date:  2012-12-05       Impact factor: 5.135

9.  Gadolinium(3+)-doped mesoporous silica nanoparticles as a potential magnetic resonance tracer for monitoring the migration of stem cells in vivo.

Authors:  Yingying Shen; Yuanzhi Shao; Haoqiang He; Yunpu Tan; Xiumei Tian; Fukang Xie; Li Li
Journal:  Int J Nanomedicine       Date:  2013-01-04

10.  Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury.

Authors:  Hyuk Min Kim; Dong Hoon Hwang; Jong Eun Lee; Seung U Kim; Byung G Kim
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.